A novel approach for estimating ingested dose associated with paracetamol overdose.

AIM In cases of paracetamol (acetaminophen, APAP) overdose, an accurate estimate of tissue-specific paracetamol pharmacokinetics (PK) and ingested dose can offer health care providers important information for the individualized treatment and follow-up of affected patients. Here a novel methodology is presented to make such estimates using a standard serum paracetamol measurement and a computational framework. METHODS The core component of the computational framework was a physiologically-based pharmacokinetic (PBPK) model developed and evaluated using an extensive set of human PK data. Bayesian inference was used for parameter and dose estimation, allowing the incorporation of inter-study variability, and facilitating the calculation of uncertainty in model outputs. RESULTS Simulations of paracetamol time course concentrations in the blood were in close agreement with experimental data under a wide range of dosing conditions. Also, predictions of administered dose showed good agreement with a large collection of clinical and emergency setting PK data over a broad dose range. In addition to dose estimation, the platform was applied for the determination of optimal blood sampling times for dose reconstruction and quantitation of the potential role of paracetamol conjugate measurement on dose estimation. CONCLUSIONS Current therapies for paracetamol overdose rely on a generic methodology involving the use of a clinical nomogram. By using the computational framework developed in this study, serum sample data, and the individual patient's anthropometric and physiological information, personalized serum and liver pharmacokinetic profiles and dose estimate could be generated to help inform an individualized overdose treatment and follow-up plan.

[1]  B. Rumack,et al.  A single-arm clinical trial of a 48-hour intravenous N-acetylcysteine protocol for treatment of acetaminophen poisoning , 2014, Clinical toxicology.

[2]  Leon Aarons,et al.  Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.

[3]  J. Wolchok,et al.  Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma , 2003, Melanoma research.

[4]  J. Hiatt,et al.  Acetaminophen hepatotoxicity and acute liver failure. , 2009, Journal of clinical gastroenterology.

[5]  S. Duffull,et al.  The Population Pharmacokinetics of Citalopram After Deliberate Self-Poisoning: A Bayesian Approach , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  P. Dargan,et al.  Reported ingested dose of paracetamol as a predictor of risk following paracetamol overdose , 2014, European Journal of Clinical Pharmacology.

[7]  Panos G Georgopoulos,et al.  Reconstructing population exposures to environmental chemicals from biomarkers: Challenges and opportunities , 2009, Journal of Exposure Science and Environmental Epidemiology.

[8]  Arthur N. Mayeno,et al.  Computational Toxicology of Chloroform: Reverse Dosimetry Using Bayesian Inference, Markov Chain Monte Carlo Simulation, and Human Biomonitoring Data , 2008, Environmental health perspectives.

[9]  S. Ozkan,et al.  Comparative dissolution testing of paracetamol commercial tablet dosage forms. , 2000, Acta poloniae pharmaceutica.

[10]  C. Klaassen,et al.  Homeostasis of sulfate and 3'-phosphoadenosine 5'-phosphosulfate in rats after acetaminophen administration. , 1992, The Journal of pharmacology and experimental therapeutics.

[11]  John D. Hunter,et al.  Matplotlib: A 2D Graphics Environment , 2007, Computing in Science & Engineering.

[12]  L. Critchley,et al.  Differences in the single‐oral‐dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects , 2005, Journal of clinical pharmacy and therapeutics.

[13]  M. Rawlins,et al.  Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration , 1977, European Journal of Clinical Pharmacology.

[14]  A. Graudins,et al.  Comparative pharmacokinetics of Panadol Extend and immediate‐release paracetamol in a simulated overdose model , 2006, Emergency medicine Australasia : EMA.

[15]  J. Lin,et al.  Dose‐dependent pharmacokinetics: Experimental observations and theoretical considerations , 1994, Biopharmaceutics & drug disposition.

[16]  Clive G. Wilson,et al.  Comparison of the Rates of Disintegration, Gastric Emptying, and Drug Absorption Following Administration of a New and a Conventional Paracetamol Formulation, Using γ Scintigraphy , 2003, Pharmaceutical Research.

[17]  G. Johanson,et al.  Using population physiologically based pharmacokinetic modeling to determine optimal sampling times and to interpret biological exposure markers: The example of occupational exposure to styrene. , 2012, Toxicology letters.

[18]  R. Day,et al.  Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. , 2014, British journal of clinical pharmacology.

[19]  L F Prescott,et al.  Inter-subject and ethnic differences in paracetamol metabolism. , 1986, British journal of clinical pharmacology.

[20]  M. Wiese,et al.  Immediate‐type hypersensitivity drug reactions , 2014, British journal of clinical pharmacology.

[21]  D. Levitt Quantitation of small intestinal permeability during normal human drug absorption , 2013, BMC Pharmacology and Toxicology.

[22]  M Rowland,et al.  Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry , 2013, CPT: pharmacometrics & systems pharmacology.

[23]  A. Graudins,et al.  The comparative pharmacokinetics of modified‐release and immediate‐release paracetamol in a simulated overdose model , 2010, Emergency medicine Australasia : EMA.

[24]  Manuela Pavan,et al.  Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen. , 2013, Toxicology letters.

[25]  Weihsueh A Chiu,et al.  Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. , 2009, Toxicology and applied pharmacology.

[26]  A. W. Hixson,et al.  Dependence of Reaction Velocity upon surface and Agitation , 1931 .

[27]  R. Raffa,et al.  Acetaminophen (Paracetamol) Oral Absorption and Clinical Influences , 2014, Pain practice : the official journal of World Institute of Pain.

[28]  C. Klaassen,et al.  Acetaminophen decreases adenosine 3'-phosphate 5'-phosphosulfate and uridine diphosphoglucuronic acid in rat liver. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[29]  P. Dargan,et al.  Impact of Restricting Paracetamol Pack Sizes on Paracetamol Poisoning in the United Kingdom , 2007, Drug safety.

[30]  L F Prescott,et al.  Kinetics and metabolism of paracetamol and phenacetin. , 1980, British journal of clinical pharmacology.

[31]  J. Perkins Acetaminophen sets records in the United States: Number 1 analgesic and number 1 cause of acute liver failure , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  Brad Reisfeld,et al.  Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[33]  B. Rumack Acetaminophen Hepatotoxicity: The First 35 Years , 2002, Journal of toxicology. Clinical toxicology.

[34]  Hans V Westerhoff,et al.  Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[35]  Gaël Varoquaux,et al.  The NumPy Array: A Structure for Efficient Numerical Computation , 2011, Computing in Science & Engineering.

[36]  J. Chan,et al.  Single-dose pharmacokinetics of paracetamol and its conjugates in Chinese non-insulin-dependent diabetic patients with renal impairment , 1997, European Journal of Clinical Pharmacology.

[37]  Leon Aarons,et al.  Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[38]  Melvin E. Andersen,et al.  In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[39]  Rotem Ben-Shachar,et al.  The biochemistry of acetaminophen hepatotoxicity and rescue: a mathematical model , 2012, Theoretical Biology and Medical Modelling.

[40]  S. Pond,et al.  Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen. , 1985, Archives of internal medicine.

[41]  M. Sivilotti,et al.  Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. , 2005, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[42]  Arthur N. Mayeno,et al.  DoseSim: a tool for pharmacokinetic/pharmacodynamic analysis and dose reconstruction , 2013, Bioinform..

[43]  R. Clark,et al.  Toxicity From Repeated Doses of Acetaminophen in Children: Assessment of Causality and Dose in Reported Cases , 2014, American journal of therapeutics.

[44]  Sergio E. Wong,et al.  Quantitative In Silico analysis of transient metabolism of acetaminophen and associated causes of hepatotoxicity in humans , 2013, In Silico Pharmacology.

[45]  Frédéric Y. Bois,et al.  GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models , 2009, Bioinform..

[46]  K. Hawton,et al.  Deliberate self-harm in young people: characteristics and subsequent mortality in a 20-year cohort of patients presenting to hospital. , 2007, The Journal of clinical psychiatry.

[47]  Stefan Willmann,et al.  Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification , 2013, In Silico Pharmacology.

[48]  M. Coughtrie,et al.  Assessment of cryopreserved human hepatocytes as a model system to investigate sulfation and glucuronidation and to evaluate inhibitors of drug conjugation , 2009, Xenobiotica; the fate of foreign compounds in biological systems.